BP8 Stock Overview
Engages in sourcing, producing, marketing, and selling traditional medicines in Australia, Singapore, China, and Malaysia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
BPH Global Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.002 |
| 52 Week High | AU$0.01 |
| 52 Week Low | AU$0.002 |
| Beta | 1.03 |
| 11 Month Change | -33.33% |
| 3 Month Change | -33.33% |
| 1 Year Change | n/a |
| 33 Year Change | -97.04% |
| 5 Year Change | -97.33% |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| BP8 | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -20.0% | -2.5% | 0.3% |
| 1Y | n/a | 16.3% | 16.1% |
Return vs Industry: Insufficient data to determine how BP8 performed against the Australian Biotechs industry.
Return vs Market: Insufficient data to determine how BP8 performed against the Australian Market.
Price Volatility
| BP8 volatility | |
|---|---|
| BP8 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: BP8's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine BP8's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Matthew Leonard | www.scu.com.sg |
BPH Global Ltd, together with its subsidiaries, engages in sourcing, producing, marketing, and selling traditional medicines in Australia, Singapore, China, and Malaysia. Its products include Caulerpa Lentillifera, a sea grape extract; Dendrobium Officinale Kimura et Migo, an orchid; Resina, a Daemonorops Draco Blume extract; and Cannabis Sativa, an industrial hemp. The company was formerly known as Stemcell United Limited and changed its name to BPH Global Ltd in June 2023.
BPH Global Ltd Fundamentals Summary
| BP8 fundamental statistics | |
|---|---|
| Market cap | AU$1.19m |
| Earnings (TTM) | -AU$1.60m |
| Revenue (TTM) | AU$109.97k |
10.8x
P/S Ratio-0.7x
P/E RatioIs BP8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BP8 income statement (TTM) | |
|---|---|
| Revenue | AU$109.97k |
| Cost of Revenue | AU$91.70k |
| Gross Profit | AU$18.27k |
| Other Expenses | AU$1.62m |
| Earnings | -AU$1.60m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.004 |
| Gross Margin | 16.61% |
| Net Profit Margin | -1,453.57% |
| Debt/Equity Ratio | -26.1% |
How did BP8 perform over the long term?
See historical performance and comparison